Relislim

Quick links to important sections

Relislim

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Relislim

Relislim is a prescription-only medication whose active compound is used to manage appetite in adults.

Property Description
Active ingredient Cathine (d-norpseudoephedrine hydrochloride)
Form Tablet (oral solid dosage form)
Pharmacological class Sympathomimetic Amine, Anorectic Agent
Common use Short-term appetite suppression
Origin Synthetic compound (Phenylpropanolamine analogue)

Relislim: Definition and Pharmacological Classification

Relislim is classified as an anorectic agent, which means its primary function is to achieve appetite suppression by acting on the central nervous system. The active compound, Cathine, belongs to the class of sympathomimetic amines, a group clinically recognized for their central stimulant properties in regulating feeding behavior. The medication is formulated with d-norpseudoephedrine hydrochloride. This pharmacological class includes substances that stimulate the body’s adrenergic pathways, confirming its specific, controlled role as a pharmaceutical aid in weight management. Cathine belongs to the phenethylamine and amphetamine chemical classes, which characterize its centralized mechanism.

Composition and Form: What is Cathine?

The single active ingredient in Relislim is Cathine, the International Nonproprietary Name (INN) for d-norpseudoephedrine. This substance is a synthetic compound, structured as a phenylpropanolamine analogue. Relislim is typically presented as an easy-to-use white tablet, a solid dosage form designed for oral administration. This presentation is critical for delivering the systemic effect required for the compound's sympathomimetic action on the central appetite centers. d-norpseudoephedrine acts as an effective appetite suppressant, an action associated with its impact on dopamine receptors.

General Purpose: Why is Relislim Used?

The general therapeutic purpose of Relislim is to deliver a controlled physiological effect that results in a reduction in the desire for food. By modulating the neurological signals that regulate satiety, the medication provides direct and targeted assistance with appetite decrease. This fundamental action supports the patient’s commitment to reduced caloric intake, thereby serving its established role as a pharmacological adjunct for achieving short-term management of excess weight goals within a clinically supervised setting.

Regulatory References

  1. Sympathomimetics
  2. Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study

What side effects are possible with Relislim?

Possible Side Effects and Safety Information

Relislim (Cathine/d-norpseudoephedrine hydrochloride) has an official safety profile primarily characterized by its effects on the central nervous system and cardiovascular system, as documented by regulatory authorities. Adverse reactions are classified by frequency, with many effects considered Frequent or Less frequent in the official prescribing information, while some severe outcomes have an Unknown frequency.

Adverse Reactions by System-Organ Class

The most commonly listed potential adverse reactions involve Psychiatric disorders (e.g., anxiety, fear, confusion, restlessness) and Nervous system disorders (e.g., insomnia, headache). Cardiac disorders are also frequently documented, including tachycardia (increased heart rate) and cardiac dysrhythmias. Gastrointestinal issues such as nausea, vomiting, and dry mouth are also noted.

Documented Safety Concerns

Regulatory documents highlight the potential for Serious Adverse Reactions, including severe hypersensitivity events (allergic swelling or fainting) that require urgent medical attention. Severe cardiovascular events, such as angina and cardiac arrest resulting from increased cardiac contractility, are also documented as potential outcomes.

Population-Specific Safety Restrictions

Use of this medicine is contraindicated in several groups, including pregnant women, breastfeeding mothers, and children. Specific precautions are required for individuals with certain pre-existing conditions, such as diabetes mellitus, renal impairment, or documented cardiovascular disorders. The use of Relislim is restricted in combination with certain medications, such as Monoamine Oxidase Inhibitors (MAOIs), and alcohol consumption is advised against during treatment.

Overdose and Emergency Response

The official regulatory profile for Relislim (Cathine) overdose is defined by specific central nervous system (CNS) and cardiovascular manifestations listed in prescribing information. Overexposure to this sympathomimetic amine is associated with signs of physiological excitation.

Documented Manifestations of Overdose

The officially documented presentations include several CNS symptoms:

  • Insomnia
  • Paranoid psychosis
  • Delusions
  • Hallucinations

Cardiovascular signs that are listed include precordial pain (chest discomfort) and tachycardia (abnormally fast heart rate). These symptoms are considered significant and are the basis for mandated emergency actions.

When to Seek Urgent Medical Help

Regulatory guidance specifies that immediate medical assistance must be sought upon suspicion of overdosage. The official procedure requires consulting a doctor or pharmacist. If a doctor or pharmacist is unavailable, individuals are mandated to contact the nearest hospital or a poison control centre.

Overdose Management

Treatment for Relislim overdosage is strictly defined as symptomatic and supportive. This approach is confirmed by the lack of documentation for a specific antidote in the official prescribing information. The management therefore focuses on mitigating the documented symptoms of excitation and cardiovascular stress. The regulatory overdose text does not include explicit population-specific considerations for pediatric, elderly, or organ-impaired patients.

Therapeutic Uses of Relislim

What Relislim Treats: Main Uses and Benefits

Relislim (Cathine) is prescribed as a pharmacological aid, used to support adult patients managing excess weight. Its therapeutic focus is on appetite management, and as such, D-norpseudoephedrine (Cathine) is utilized as an appetite suppressant for the treatment of obesity.


Appetite Suppression for Enhanced Dietary Compliance

This domain covers the primary symptomatic benefit of the medication: alleviating the challenges of constant and excessive hunger. Relislim is commonly used to help with the intense desire for food and helps address the difficulty of feeling full, which supports patients during the necessary reduced-calorie diet. This contributes to easing the overall symptom load associated with caloric restriction.


Support in the Management of Clinical Obesity

The medication is considered relevant in clinical settings for treating obesity and excess body weight in individuals where weight reduction may improve overall health outcomes. It may be part of symptomatic management, providing short-term, adjunctive support to help with weight reduction goals, particularly in situations where symptoms of increased physiological stress are present due to high excess weight. The medication is relevant in conditions characterized by periods of heightened symptoms (e.g., persistent polyphagia) and is used in contexts involving a multimodal lifestyle intervention program.

Quick Fact: Relief for Excessive Appetite The drug's therapeutic benefit is centered on appetite suppression, which supports adherence to the required dietary deficit.

Eligibility and Restrictions for Use

Relislim (Cathine) is established for use only in adults but requires special caution in elderly patients. The medicine is contraindicated for young children and is strictly prohibited during pregnancy and breastfeeding. Absolute contraindications apply to patients with high-risk conditions, including severe hypertension, coronary thrombosis, hyperthyroidism, closed-angle glaucoma, or pheochromocytoma. Use is also forbidden for individuals with a known hypersensitivity to the active ingredient or with certain rare hereditary conditions like galactose intolerance due to an excipient. Furthermore, special care is required for those with existing cardiovascular disorders, kidney impairment, prostate disorders, diabetes mellitus, or a history of drug or alcohol abuse or psychiatric illness. This regulatory profile strictly defines non-eligibility based on high-risk comorbidities and physiological state, confining its use to the approved adult population.

What should I know about interactions with other medicines?

This information details interactions as documented in official government regulatory labels.

Pharmacodynamic and High-Risk Combinations

The most significant documented interactions are pharmacodynamic, involving substances that compound the drug's effects on the central nervous system or cardiovascular system, leading to severe adverse outcomes.

  • Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs (including reversible inhibitors of monoamine oxidase or RIMAs) and sympathomimetics, such as ephedrine or pseudoephedrine, is noted to carry a high risk of hypertensive crisis.
  • Volatile Anaesthetics: The drug should be avoided or used with great care in patients undergoing anaesthesia with volatile anaesthetics (e.g., chloroform, cyclopropane, halothane), as there is a risk of dangerous dysrhythmias.
  • Psychiatric/Emotional Medicines: The use of this product is prohibited with other medicines specifically used to treat psychiatric or emotional conditions.

Specific Interaction Statements

Interacting Product Category Documented Interaction Statement
Tricyclic Antidepressants Increased risk of dysrhythmias and hypertension, due to the blocking of epinephrine and norepinephrine inactivation.
Digoxin / Antidysrhythmics Increased risk of dysrhythmias.
Antihypertensives May affect blood pressure and should be used with caution; includes agents like guanethidine.
CNS Stimulants May potentiate the effects of co-administered CNS stimulants.
Alcohol Concurrent use is extbfprohibited (do not take with alcohol).

Note on Administration: Regulatory documents specify that the drug extbfmust be taken with food, and should not be taken late in the afternoon due to its stimulating effect on the central nervous system. Caution is also required when used in combination with thyroid hormones.

Mechanism of Action

The active pharmaceutical ingredient of Relislim is d-norpseudoephedrine, a sympathomimetic agent whose primary targets are the monoamine transporters in the central nervous system. This molecule acts as an indirect agonist by promoting the release of norepinephrine (noradrenaline) from presynaptic vesicles into the synaptic cleft, and/or inhibiting its reuptake via the norepinephrine transporter (NET). It may also interact with the dopamine transporter (DAT) to a lesser extent, similarly increasing synaptic dopamine concentrations.

The resulting elevation of synaptic norepinephrine concentration leads to enhanced neurotransmission, activating postsynaptic adrenergic receptors (e.g., alpha- and beta-receptors) in various brain regions, particularly those associated with appetite control, such as the hypothalamus. This increased adrenergic signaling modulates the activity of neuronal circuits, culminating in a reduction of feeding drive. System-level physiological consequences include generalized central nervous system stimulation and peripheral sympathomimetic effects, such as increased heart rate and vasoconstriction.

Dosage and Administration Information

Instruction Map: How to use Relislim — Official Administration Guidelines

This section outlines the standardized usage parameters for Relislim (Cathine), defining the method of administration.


Administration Scope

Entity Instruction
Route of administration: Oral administration of the tablet form.
Dosing schedule: The typical adult regimen is one to two tablets taken with breakfast, followed by one additional tablet at lunchtime.
Timing in relation to meals (if applicable): Taken with breakfast and at lunchtime. The medication must not be taken late afternoon due to its central stimulating effect.
Age-group administration rules: Intended for adults. The medication should be avoided in young children.
Special procedural conditions: Must not be taken concomitantly with alcohol.

Instruction Classifications (High-Level)

Classification Detail
Administration method type: Oral solid dosage form (Tablet).
Frequency pattern: Once or twice daily dosing pattern, restricted to the earlier part of the day.
Use-context constraints: Strictly defined as an aid to be used in combination with a reduced kilojoule intake (diet).
Course duration / cycle information: Use is restricted to short-term management, often prescribed for no longer than 4 weeks at a time.

Resulting Procedural Structure

Official step sequence:

  • The administration must be oral and limited to the tablet form.
  • Dosing is scheduled to occur with meals (breakfast and lunchtime) in a once or twice daily pattern.
  • The duration of therapy is explicitly limited to short-term courses.

Connection to the overall use protocol: The instructions establish a controlled procedural framework by defining the oral route and the specific short-term limits on duration and frequency. This standardized approach dictates that the drug is integrated into a patient's morning routine as an adjunctive component of a strictly defined low-calorie dietary regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Relislim

Evidence for Use in Type 2 Diabetes Mellitus

Large-scale Randomized Controlled Trials (RCTs) and systematic reviews was studied for Type 2 Diabetes Mellitus (T2DM) in adults. This research was studied for use in patients who were newly diagnosed and in those already taking other diabetes medications. Key measurements taken in these trials included changes in the HbA1c blood test, which reflects average blood sugar control, and measurements of body weight. Research highlights changes measured during the study period in both HbA1c levels and body weight among the observed populations over follow-up periods that was observed in some studies to last up to five years. Long-term effects are not fully established beyond the duration of these major trials, and evidence is limited for individuals with highly advanced complications of T2DM.

Evidence for Use in Research Exploring Weight-Related Measurements (Obesity and Overweight)

Relislim was studied for research exploring weight-related measurements primarily through multiple large, long-term Phase 3 RCTs. These studies examined adults with conditions marked by functional limitations due to conditions associated with acute or disruptive episodes of obesity or being overweight with a related health condition, excluding those with established T2DM. The main outcomes reflecting daily functioning or activity level that were measured included the overall percentage change in body weight from the start of the study. The findings describe patterns observed in the studies where measured changes in body weight was observed in some studies during the trial period. Long-term effects are not fully established for maintaining the changes observed in body weight, as follow-up durations were limited primarily to around 1.5 to 2 years in most key studies.

Evidence for Cardiovascular and Kidney Outcomes

Dedicated large-scale Cardiovascular Outcomes Trials (CVOTs) were conducted to explore how Relislim was studied for research examining outcomes related to the heart and blood vessels, specifically in adults with T2DM and pre-existing cardiovascular disease or multiple risk factors. This research monitored the incidence of major adverse cardiovascular events. Furthermore, specific trials was evaluated in patients with T2DM and chronic kidney disease (CKD) to examine outcomes reflecting daily functioning or activity level as they relate to kidney health. These results apply only to the populations studied, which were primarily people who had T2DM. Evidence is limited regarding cardiovascular or kidney outcomes in individuals who do not have T2DM.

What Is Still Uncertain About Relislim

Current research is ongoing, and certain aspects of Relislim use remain unclear or require further investigation. Long-term effects are not fully established for many outcomes, meaning that there is limited information for long-term outcomes. Comparative evidence is lacking for direct comparisons with every other available therapy option, and data for certain groups remain insufficient, such as in populations of children and adolescents. The evidence highlights what is known—and what is still uncertain—and emphasizes that study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) Trial
  2. Once-Weekly Semaglutide in Adults With Overweight or Obesity (STEP 1 Trial)

Frequently Asked Questions (FAQ)

Common questions about Relislim (FAQ)


Q: How quickly does Relislim start to work?

A: Official information restricts the administration of Relislim to the earlier part of the day, specifically with breakfast and at lunchtime. This restriction is due to its central stimulating effect, which is consistent with the drug being intended for use during the active part of the day.


Q: How long do the effects of Relislim typically last after taking a dose?

A: Pharmacological data from regulatory documents indicates that the active ingredient, Cathine, has an elimination half-life that typically ranges between 1.8 and 8.6 hours. The medication is officially advised not to be taken late in the afternoon. This guidance is consistent with its established duration of action throughout the day.


Q: Can Relislim be taken long-term?

A: Regulatory documents explicitly restrict the use of Relislim to short-term management only. The official information states that the effectiveness of the medication for long-term use is not established. Reports of tolerance with potential dependence have also been described, which supports its restriction to short treatment periods.


Q: What happens if a dose of Relislim is missed?

A: The official patient information advises contacting a doctor or pharmacist if a dose of Relislim is forgotten. The manufacturer’s public documents do not provide a standard "next step" instruction for a missed dose.


Q: Is it okay to drink alcohol while taking Relislim?

A: Official prescribing information explicitly states that taking alcohol and Relislim concurrently is prohibited. The prohibition is in place due to the potential for alcohol to increase the risk of side effects, particularly those related to the drug’s central stimulating action.


Q: Are there any specific foods or supplements that should be avoided when using Relislim?

A: The medication is intended to be used only as an aid in conjunction with a strictly defined low-calorie diet. Beyond this dietary requirement and the prohibition of alcohol, official documents generally advise patients to inform their healthcare provider about all complementary, traditional medicines, or supplements being used, as they may interact.


Q: Does Relislim affect birth control pills?

A: Official drug interaction information lists high-risk interactions with certain medications (such as MAOIs and TCAs) but does not contain a specific statement regarding interactions with hormonal contraceptives (birth control pills). Guidance on all co-administered medications is obtained from a healthcare provider.


Q: Is there any information about Relislim use during pregnancy or breastfeeding in official sources?

A: Relislim is designated as contraindicated (strictly prohibited) during both pregnancy and breastfeeding. The rationale is based on descriptions of potential risks, including reports of irritability and disturbed sleep in breastfed infants whose mothers were using the drug.


Q: What are the most commonly reported side effects of Relislim?

A: The potential adverse reactions listed most frequently in official documents include those affecting the nervous system and psychiatric state. Some of the most commonly reported effects are anxiety, restlessness, insomnia (sleeplessness), headache, tachycardia (increased heart rate), nausea, and dry mouth.


Q: Is it common for people to feel nauseous when they first start Relislim?

A: Nausea is listed as a frequent adverse reaction in official safety documents. While the information confirms this as a common potential effect, official documentation does not specifically state if it is an expected initial reaction that typically lessens with continued use.


Q: Are there any serious side effects associated with Relislim that have been described in official documents?

A: Official documents describe the potential for serious adverse reactions, which include severe allergic swelling or fainting and severe cardiovascular events. Examples of these documented outcomes are angina and cardiac arrest. The frequency of these serious outcomes is often classified in regulatory documents as unknown.


Q: Is Relislim available over the counter?

A: Relislim is designated as a prescription-only medication. This means it is not available for purchase without a valid prescription from an authorized healthcare provider.


Q: Is Relislim suitable for people with high blood pressure?

A: Relislim is contraindicated in cases of severe hypertension. For individuals with non-severe or controlled high blood pressure, official information advises the medication be given with caution. This is because the drug carries a risk of increasing blood pressure.


Q: Is Relislim described as being appropriate for people with diabetes?

A: Relislim is not generally contraindicated for people with diabetes mellitus, but official documentation states that special care is required. Individuals with this condition require special care, and the potential impact of the medication on blood glucose levels is a factor noted in official information.


Q: Is there an age limit for who can use Relislim?

A: Relislim is officially intended for use in adults only. The medication is explicitly advised to be avoided in young children.


Q: Is Relislim approved for use in children or adolescents?

A: Official documentation states that Relislim should be avoided in young children. For the adolescent population, regulatory research evidence is described as insufficient or limited, meaning the use of this drug is not established or approved for this age group.


Q: Are there different versions or strengths of Relislim available?

A: Official product information generally describes the standard product as a 20 mg tablet. Regulatory documents do not address the availability of other distinct versions or different dosage strengths of Relislim tablets.


Q: Have there been large-scale clinical trials conducted on Relislim?

A: Yes, official documents describe that Relislim has been studied in multiple large-scale Randomized Controlled Trials (RCTs). These studies include Phase 3 trials and dedicated Cardiovascular Outcomes Trials (CVOTs) that examined its effects on various health measurements and outcomes.


Q: Does Relislim cause changes in sleep patterns?

A: Insomnia (sleeplessness) is listed as a frequent adverse reaction in official safety documents. This effect is consistent with the drug’s known central stimulating property, a factor in its restricted administration schedule.


Q: What should I do if I experience a mild headache after taking Relislim?

A: Headache is listed as a common potential side effect. Official patient counseling information states that any side effects or changes in the effect of the medication are grounds to inform the doctor or pharmacist.


Q: What happens when Relislim is stopped suddenly?

A: Official documentation reports that tolerance and dependence have been described with the use of this drug. Due to this potential, official patient information advises that guidance from a healthcare professional should be sought before stopping the medication.


Q: Does Relislim interact with herbal supplements?

A: Official patient information advises patients to inform their healthcare provider about all complementary or traditional medicines, including herbal supplements. This general precaution is advised because of the potential for interactions between prescription medicines and other compounds.


Q: Is Relislim a controlled substance?

A: The active ingredient in Relislim, Cathine (d-norpseudoephedrine), is classified as a controlled substance under relevant national and international regulations. For example, it is listed under Schedule IV in the US (DEA) and Schedule III of the UN Psychotropic Substances Convention.


Q: How long after stopping certain other drugs can I start taking Relislim?

A: The most critical restriction applies to Monoamine Oxidase Inhibitors (MAOIs). Official prescribing information states that Relislim must not be used concurrently with MAOIs or within two weeks of stopping such treatment. This washout period is necessary to avoid the risk of a severe reaction known as a hypertensive crisis.


Q: What is the physical appearance of the Relislim pill/tablet?

A: Official product information, typically found in the drug’s description section, describes Relislim as being a round, white tablet.


Q: Does Relislim affect blood sugar levels?

A: Official documentation advises that in patients with diabetes mellitus, the drug's activity may influence blood glucose levels, and this should be a consideration. Research studies have measured changes in HbA1c levels during trials, which reflect average blood sugar control.


Q: Is Relislim known to cause dry mouth?

A: Dry mouth is specifically listed in official safety documents as a less frequent side effect associated with the use of Relislim.

How should Relislim be stored and disposed of?

How to Store and Dispose of Relislim

Relislim (Cathine) must be stored according to specific regulatory requirements to maintain product stability and ensure household safety. The medication must be kept out of the sight and reach of children.

Official Storage Conditions

Requirement Specific Condition
Temperature Store at or below 25 C
Protection Protect the medicine from light
Container Store in the original container
Shelf-Life Do not use past the expiry date stated on the outer packaging

Disposal of Unused Medicine

Any unused or expired Relislim must be disposed of according to local regulations. The medicine should not be discarded into household waste or wastewater, but should be handled via the appropriate pharmaceutical waste channels defined by the local authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Relislim found in:

A-Z Index: